Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

8.20USD
12:39pm EST
Change (% chg)

$0.05 (+0.61%)
Prev Close
$8.15
Open
$8.04
Day's High
$8.26
Day's Low
$8.00
Volume
21,358
Avg. Vol
29,194
52-wk High
$23.68
52-wk Low
$5.51

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics Qtrly Loss Per Share $0.38
Tuesday, 6 Nov 2018 04:23pm EST 

Nov 6 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.PROTAGONIST THERAPEUTICS - HEPCIDIN MIMETIC PTG-300 ON TRACK FOR INITIATION OF OPEN LABEL, PHASE 2 TRIAL IN BETA-THALASSEMIA PATIENTS BY YEAR END.PROTAGONIST THERAPEUTICS INC QTRLY LOSS PER SHARE $0.38.PROTAGONIST THERAPEUTICS QTRLY LICENSE AND COLLABORATION REVENUE- RELATED PARTY $6.1 MILLION VERSUS $8.8 MILLION.PROTAGONIST THERAPEUTICS INC - EXPECTS TO HAVE SUFFICIENT FINANCIAL RESOURCES TO FUND OPERATIONS TO MID-2020..  Full Article

Protagonist Therapeutics Q4 Loss Per Share $0.15
Wednesday, 7 Mar 2018 04:02pm EST 

March 7 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.PROTAGONIST THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.15.PROTAGONIST THERAPEUTICS - ANTICIPATE HAVING ENOUGH CASH, CASH EQUIVALENTS, INVESTMENTS TO SUPPORT OPERATIONS THROUGH 2019.  Full Article

FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300
Tuesday, 6 Mar 2018 04:30pm EST 

March 6 (Reuters) - Protagonist Therapeutics Inc ::FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA.  Full Article

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Wednesday, 11 Oct 2017 10:26pm EDT 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Wednesday, 11 Oct 2017 04:01pm EDT 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article

Protagonist Therapeutics announces preliminary phase 1 study results with PTG-300
Wednesday, 20 Sep 2017 08:00am EDT 

Sept 20 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces preliminary phase 1 study results with novel hepcidin mimetic, PTG-300.Protagonist Therapeutics Inc - ‍expect to report final top line results of amended PTG-300 study in Q4 of 2017​.Protagonist - ‍PTG-300 showed dose-dependent increase in blood exposure, was well tolerated, with no serious adverse events or dose-limiting toxicities​.  Full Article

Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​
Friday, 1 Sep 2017 04:51pm EDT 

Sept 1 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​.  Full Article

Protagonist Therapeutics announces closing of Janssen license
Thursday, 24 Aug 2017 04:01pm EDT 

Aug 24 (Reuters) - Protagonist Therapeutics Inc ::Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment.Protagonist Therapeutics - ‍following closure of transaction, co received upfront payment of $50 million originally announced by two cos as part of agreement.Protagonist Therapeutics Inc - ‍PTG-200 is expected to enter phase 1 clinical testing before end of 2017​.  Full Article